Please use this identifier to cite or link to this item: https://doi.org/10.1159/000346234
Title: The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES) for the NEURITE investigators
Authors: Chen, C.L.H.
Ikram, K.
Anqi, Q. 
Yin, W.T. 
Chen, A.
Venketasubramanian, N.
Keywords: Cognitive impairment
MLC601
MLC901
NeuroAiD
Neurogenesis
Neuroplasticity
Neuroprotection
Stroke
Issue Date: Mar-2013
Citation: Chen, C.L.H., Ikram, K., Anqi, Q., Yin, W.T., Chen, A., Venketasubramanian, N. (2013-03). The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES) for the NEURITE investigators. Cerebrovascular Diseases 35 (SUPPL.1) : 23-29. ScholarBank@NUS Repository. https://doi.org/10.1159/000346234
Abstract: Background: A substantial proportion of patients after nondisabling stroke are cognitively impaired compared to age- and education-matched community-dwelling controls. Moreover, poststroke patients who have 'vascular cognitive impairment no dementia' (VCIND) of moderate severity have a high risk of incident dementia, dependency and death. Further studies are urgently needed to demonstrate effective cognition-enhancing therapies in VCIND given the scarcity of evidence-based treatment options. NeuroAiD is a traditional Chinese medicine that has been shown to induce neuroplasticity, promote cell proliferation and stimulate the development of dense axonal and dendritic networks in animal stroke models. NeuroAiD may improve cerebral blood flow and functional recovery after stroke in patients. Objective: To investigate the effects and tolerability of NeuroAiD II in patients with VCIND. Methods: The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES) is a 24-week, double-blind, randomized, placebo-controlled phase II study of NeuroAiD II in patients with VCIND. The primary outcome is executive function as measured by the Verbal Fluency test. Secondary outcomes include cognitive assessments such as the ADAS-Cog, MoCA, MMSE and Cognitive Battery: activities of daily living as measured by the Alzhei-mer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale for mild cognitive impairment, behavior as measured by the Neuropsychiatric Inventory, and depression as measured by the Geriatric Depression Scale and the Beck Depression Scale. In addition, there will be novel exploratory outcomes: (a) magnetic resonance imaging of lesion location (structural imaging), structural integrity of white matter pathways (diffusion tensor imaging), neuronal function (resting studies) and perfusion (arterial spin labeling and MR angiography), and (b) retinal and optic nerve imaging. Safety and tolerability will be assessed using adverse events, laboratory tests and vital signs. Conclusions: NEURITES has the potential to set new standards for the systematic evaluation of Asian traditional medicine for integration into standard medicine practice and establishing a novel therapeutic approach for improving cognition after stroke. Copyright © 2013 S. Karger AG, Basel.
Source Title: Cerebrovascular Diseases
URI: http://scholarbank.nus.edu.sg/handle/10635/52559
ISSN: 10159770
DOI: 10.1159/000346234
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

7
checked on Jul 14, 2018

WEB OF SCIENCETM
Citations

7
checked on Jun 19, 2018

Page view(s)

97
checked on Jul 6, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.